11 May 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will (re)consider the reimbursement of:

• Triptorelin acetate (Decapeptyl)
  
• Alectinib hydrochloride (Alecensa)
  
• Olaratumab (Lartruvo)
  
• Ofatumumab acetate (Arzerra)
  
• Coagulation factor VIII (human) with von Willebrand factor (human) (Eqwilate)
  
• Tocilizumab (RoActemra)
  

Read TC agenda [French]